Urology Medical News about tumor markers

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Beyond PSA: Utility of novel tumor markers in the setting of elevated PSA
Urologic Oncology: Seminars and Original Investigations, 07/01/09

Lin DW - In a review of the utility of novel tumor markers in the setting of elevated prostate-specific antigen (PSA), this article will first highlight several characteristics of an ideal biomarker, then focus on select emerging biomarkers for detection of prostate cancer (PCa).

Methods

Introduction of prostate-specific antigen (PSA) for PCa screening and detection has been used for over 20 yrs and has dramatically changed the face of PCa.
Although it is a highly sensitive serum test, its routine use has been the subject of continued controversy owing to its limited specificity.

Results

Due to this lack of specificity, many have proposed modifications of PSA in an attempt to bolster the performance of this analyte.
The human genome project and high throughput gene expression profiling has recently yielded several promising molecular biomarkers for PCa detection beyond PSA or PSA modifications.

<< Previous
The expression of Twist has an impact on survival in human...

Next >>
Investigation of a new 1,3-diarylpropenone as a potential...